Thymol has beneficial effects on the experimental model of ulcerative colitis
<strong>Objective:</strong> Thymol, a natural aromatic monoterpene phenol derived from thymus, possesses anti-inflammatory benefits. Here, we evaluated the potential of thymol therapy in improving an animal model of ulcerative colitis.<br /> <strong>Materials and Methods:<...
Sábháilte in:
| Príomhchruthaitheoirí: | , , |
|---|---|
| Formáid: | LEABHAR |
| Foilsithe / Cruthaithe: |
Mashhad University of Medical Sciences,
2019-10-01T00:00:00Z.
|
| Ábhair: | |
| Rochtain ar líne: | Connect to this object online. |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
| Achoimre: | <strong>Objective:</strong> Thymol, a natural aromatic monoterpene phenol derived from thymus, possesses anti-inflammatory benefits. Here, we evaluated the potential of thymol therapy in improving an animal model of ulcerative colitis.<br /> <strong>Materials and Methods:</strong> Luminal instillation of acetic acid was used to induce colitis in male Wistar rats. Treatment groups daily received prednisolone (2 mg/kg, orally) or thymol (100 mg/kg, orally) for 10 consecutive days. Then, the rats were euthanized and tissue specimens were collected for evaluation of cyclooxygenase-2 (COX-2) expression by immunohistochemistry. Furthermore, the levels of total protein, nitric oxide, myeloperoxidase, malondialdehyde, IL-1, IL-6, and TNF-α were monitored in colonic homogenates. Eventually, the relative mRNA expression of <em>IκBα </em>and <em>NF-κBp65</em> was investigated using reverse-transcriptase PCR (RT-PCR) in colonic homogenates.<br /> <strong>Results:</strong> Both medications could reduce the mortality rate and the clinical scores of ulcerative colitis. The COX-2 expression was significantly reduced in the colons of thymol-treated animals compared to the prednisolone group. Also, the myeloperoxidase activity, nitric oxide level and malondialdehyde intensity were decreased in the colons of thymol-treated animals to a greater extent compared to the prednisolone group. Moreover, the total protein content of guts showed significant increases in the guts of thymol-treated animals in comparison to the prednisolone group. Nonetheless, thymol significantly reduced the levels of IL-6, and IL-1 compared to prednisolone. Both medications caused a significant decrease in the mRNA level of <em>NF-κBp65</em>, though the mRNA level of <em>IκBα</em> did not show significant changes between the groups.<br /> <strong>Conclusion:</strong> Thymol may be a promising agent to ameliorate ulcerative colitis. |
|---|---|
| Cur síos ar an mír: | 2228-7930 2228-7949 10.22038/ajp.2019.13383 |